

Board of Directors Meeting in Public - Cover Sheet

Subject:	Research and Development Performance and Strategy Update Report – Q1&2, 2023		Date: 5th October 2023		
Prepared By:	Alison Steel, Head of Research and Innovation				
Approved By:	Elizabeth Gemmill, Director of Research, and Innovation				
Presented By:	Alison Steel, Head of Research and Innovation				
Purpose					
To present the Research and Innovation Q1&2 Performance and strategy update report				Approval	
				Assurance	X
				Update	X
Update and assurance on performance, strategic priorities, patient experience and financial position.				Consider	
Strategic Objectives					
Provide outstanding care in the best place at the right time	Improve health and well-being within our communities	Empower and support our people to be the best they can be	To continuously learn and improve	Sustainable use of resources and estate	Work collaboratively with partners in the community
X		X	X		X
Principal Risk					
PR1	Significant deterioration in standards of safety and care				
PR2	Demand that overwhelms capacity				
PR3	Critical shortage of workforce capacity and capability				
PR4	Failure to achieve the Trust's financial strategy				
PR5	Inability to initiate and implement evidence-based Improvement and innovation				X
PR6	Working more closely with local health and care partners does not fully deliver the required benefits				X
PR7	Major disruptive incident				
PR8	Failure to deliver sustainable reductions in the Trust's impact on climate change				
Committees/groups where this item has been presented before					
None					
Acronyms					
List all acronyms used within the report.					
ICB = Integrated Care Board					
ICS = Integrated Care System					
EMCRM= East Midlands Clinical Research Network					
CRN = Clinical Research Network					
NIHR= National Institute Clinical Research					
R&I=Research and Innovation					
IAOCR = International Accrediting Organisation for Clinical Research					
NTU = Nottingham Trent University					
NUH= Nottingham University Hospital's					
GCP= Good Clinical Practice					
CRO= Contract Research Organisation					
Executive Summary					
Performance Metrics					
<ul style="list-style-type: none"> • 3,310 participants recruited into research studies compared to 1,138 this time last year, 121 studies on the SFH portfolio. • Confirmed £793, 206.86 EMCRN 2023/24 budget. • Commercial income at Q2 £31,318.23 					

Patient Experience

- 94% of participants Agree/Strongly Agree their participation in research has been valued.
- 90% of participants would consider taking part in research again.
- All Participants Agree/Strongly Agree that they have been treated with courtesy and respect.

Research Strategy update 22-27 Year 1& 2 Priority Objectives

Progress:

- 1.1 Collaboration with EMCRN & commercial sponsors to increase commercial research opportunities
- 1.2 Streamline the set-up process for faster delivery

Place:

- 2.1 Open a new Clinical Research Facility at Kings Mill Hospital in 2023 for early phase clinical trials of new drugs, devices, and diagnostics
- 2.2 Host the Nottinghamshire Mobile Research Unit to deliver place based research in our community

People:

- 3.1 Further develop the role of the Research Academy and research opportunities for SFH staff.
- 3.2 Investment in our management workforce to ensure a sustainable future for research and future developments

Partnerships:

- 4.1 Increase our academic and industry partnerships to maximise mutual benefits from collaboration